Price Chart

Profile

Ultragenyx Pharmaceutical Inc is a USA-based biopharmaceutical company. It identifies, acquires, develops, and commercializes novel products for the treatment of serious rare and ultra-rare diseases, with a focus on serious, debilitating genetic diseases. The company's medicine portfolio includes Crysvita, Dojolvi, and Mepsevii. Crysvita is indicated for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients 1 year of age and older. Mepsevii is indicated in pediatric and adult patients for the treatment of Mucopolysaccharidosis VII.
URL https://www.ultragenyx.com
Investor Relations URL https://ir.ultragenyx.com/
HQ State/Province California
Sector Healthcare
Industry Biotechnology
Equity Style Small Cap/Blend
Next Earnings Release May. 03, 2024 (est.)
Last Earnings Release Feb. 15, 2024
Next Ex-Dividend Date N/A
Last Ex-Dividend Date N/A

Profile

Ultragenyx Pharmaceutical Inc is a USA-based biopharmaceutical company. It identifies, acquires, develops, and commercializes novel products for the treatment of serious rare and ultra-rare diseases, with a focus on serious, debilitating genetic diseases. The company's medicine portfolio includes Crysvita, Dojolvi, and Mepsevii. Crysvita is indicated for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients 1 year of age and older. Mepsevii is indicated in pediatric and adult patients for the treatment of Mucopolysaccharidosis VII.
URL https://www.ultragenyx.com
Investor Relations URL https://ir.ultragenyx.com/
HQ State/Province California
Sector Healthcare
Industry Biotechnology
Equity Style Small Cap/Blend
Next Earnings Release May. 03, 2024 (est.)
Last Earnings Release Feb. 15, 2024
Next Ex-Dividend Date N/A
Last Ex-Dividend Date N/A